UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS泌尿肿瘤学：专题与原创研究
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS(英文缩写 UROL ONCOL-SEMIN ORI),ISSN 1078-1439,eISSN 1873-2496,中文译名:泌尿肿瘤学：专题与原创研究 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 2.954 | Q3 |
| 2022 | 2.700 | Q2 |
| 2023 | 2.400 | Q2 |
| 2024 | 2.300 | Q2 |
| 2025 | 2.800 | Q2 |
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 最新收录文献
-
1. Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
PMID:日期:2026-10-03There is substantial heterogeneity of outcomes among patients with high-risk localized prostate cancer. The recently published PROTEUS trial saught to enrich for aggressive disease using more restrictive eligibility criteria than the commonly used NCCN high-risk definition. We compared patient distributions and oncologic outcomes after radical prostatectomy using PROTEUS and NCCN high-risk criteria. We used an institutional radical prostatectomy database to classify patients as high-risk by NCCN criteria (Gleason grade group [GGG] 4-5, clinical T3-T4 disease, or PSA > 20 ng/ml) or PROTEUS criteria (overall GGG ≥ 3 plus GGG5 in ≥1 core, GGG4 in ≥2 cores each with >80% involvement, GGG3+ in ≥6 systematic cores, or GGG3+ in ≥3 systematic cores with PSA ≥ 20 ng/ml). Patient distributions were summarized descriptively. Area under the receiver operating curve (AUC) was compared for oncologic outcomes. Among 358 patients, 62 (17%) met NCCN high-risk criteria and 44 (12%) met PROTEUS criteria. Overall, 38 patients met both definitions, 24 met NCCN criteria only, and 6 met PROTEUS criteria only. There were no statistically significant differences in predicting extra-prostatic extension (NCCN 0.56, 95% Confidence interval [CI] 0.52-0.60; PROTEUS 0.56, 95% CI 0.53-0.60; P = 0.96), positive surgical margins (NCCN 0.54, 95% CI 0.49-0.58; PROTEUS 0.52, 95% CI 0.49-0.56; P = 0.45), and PSA > 0.2 at 12 months postoperatively (NCCN 0.59, 95% CI 0.49-0.69; PROTEUS 0.64, 95% CI 0.54-0.75; P = 0.32). PROTEUS criteria, which may be cumbersome in clinical practice, identified a smaller, overlapping, but nonidentical high-risk population compared with NCCN criteria. There were no statistically significant differences in postprostatectomy oncologic outcomes between both definitions. These findings suggest that PROTEUS eligibility criteria represent a more restrictive trial-enrichment definition but may not meaningfully improve discrimination of adverse outcomes relative to standard NCCN high-risk classification.
-
2. Sociodemographic barriers to receiving adjuvant systemic therapy after nephrectomy for renal cell carcinoma.
PMID:日期:2026-10-01It is unknown whether sociodemographic barriers affect the use of adjuvant systemic therapy after nephrectomy among eligible renal cell carcinoma patients. Within Surveillance, Epidemiology, and End Results database, we identified renal cell carcinoma patients eligible for adjuvant systemic therapy after nephrectomy between 2018 and 2022. Multivariable logistic regression models assessed associations between age, marital status, race/ethnicity, and adjuvant systemic therapy use. Of 6,497 eligible patients, 1,163 patients (17.9%) received adjuvant systemic therapy. Treatment rates were lower in patients aged ≥65 years (14.9% vs. 21.2%, odds ratio [OR] 0.60, 95% confidence interval [CI]: 0.52-0.68, P < 0.001), unmarried individuals (15.9% vs. 19.0%, OR 0.75, 95% CI: 0.65-0.87, P < 0.001), and non-Caucasian patients (16.3% vs. 18.7%, OR 0.75, 95% CI: 0.65-0.87, P < 0.001), even after multivariable adjustment for other patient and tumor characteristics. Combined assessment of these 3 sociodemographic characteristics demonstrated a stepwise decrease in treatment rates, that were lowest in ≥65-year-old unmarried non-Caucasians (10.4%, OR 0.29, 95% CI: 0.19-0.41, P < 0.001) and highest in <65-year-old married Caucasians (24.2%, reference). Despite guideline endorsement, only a minority of eligible renal cell carcinoma patients receive adjuvant systemic therapy after nephrectomy. Older age, unmarried status, and non-Caucasian race/ethnicity were independently associated with lower adjuvant systemic therapy receipt. The combination of these established sociodemographic barriers identified the patient subgroup with the lowest likelihood of receiving adjuvant systemic therapy. Efforts aimed at reducing disparities and close gaps in the implementation of guideline-recommended adjuvant systemic therapy use should therefore focus on individuals with this sociodemographic profile.
-
3. Re: Trans-perineal prostate biopsy-prognostic factors for "no prostate tissue" in biopsy cores: Beyond local anesthesia.
3. 回复：活检核心中“无前列腺组织”的经会阴前列腺活检预后因素：局部麻醉之外PMID:日期:2026-10-01该文献暂无摘要。
-
4. Corrigendum to "Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition" Volume 35, Issue 10, October 2017, Pages 593-599.
4. 对“膀胱癌细胞系亚型中mTOR通路差异表达谱预测对mTOR抑制敏感性的研究”的勘误，第35卷，第10期，2017年10月，第593-599页PMID:日期:2026-10-01该文献暂无摘要。
-
5. Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy.
5. 美国癌症膀胱癌根治术患者的真实世界ctDNA检测利用率和相关费用PMID:日期:2026-09-29Circulating tumor DNA (ctDNA) can inform prognosis and treatment effectiveness in bladder cancer. We evaluated real-world utilization and costs of ctDNA testing among US patients with bladder cancer undergoing radical cystectomy following initiation of Medicare coverage for ctDNA testing. Using claims data from Optum Clinformatics Data Mart Database (January 19, 2022-June 30, 2025) covering commercial and Medicare Advantage plans, we evaluated ctDNA testing incidence, testing rate, and costs in patients undergoing radical cystectomy. Total (paid by payers and patients) and out-of-pocket costs (sum of coinsurance, copays, and deductibles) were reported. Time to first and second tests was estimated using Kaplan-Meier methods. Patient characteristics were evaluated among those who received ≥1 ctDNA test vs. untested patients. Among 1,995 patients (76.4% male; 89.1% White), 17.1% (341/1995) received ≥1 ctDNA test before (4.7%) and/or after (14.7%) radical cystectomy (median of 2 tests among those tested; Q1-Q3: 1-5). Median testing cost was $4,178 (Q1-Q3: $1,756-$4,178), with $0 median out-of-pocket cost. Testing rate rose from 4.0 (second half of 2022) to 34.0 (first half of 2025) tests per 1,000 patient-months (P for trend <0.001). Tested and untested cohorts had similar age, sex, and race distributions. Tested patients were more likely to receive systemic treatment before (46.0% vs. 35.8%, P < 0.001) and after cystectomy (24.0% vs. 10.1%, P < 0.001) than untested patients. Since Medicare coverage approval, ctDNA testing among US radical cystectomy-treated patients with bladder cancer has increased steadily but remains modest. Total costs varied, yet patient out-of-pocket expenses were minimal.
-
6. Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer.
PMID:日期:2026-09-26Comprehensive geriatric assessments (CGA) inform risk stratification in bladder cancer (BC) care but are time- and resource-intensive. To investigate whether body composition analysis (BCA) on computed tomography (CT) is associated with CGA. Patients with BC (any stage) were enrolled in a prospective observational cohort study between September 2020 and July 2021. Patients completed CGA, including grip strength (GS), Timed Up and Go (TUG), and Clinical Frailty Scale. BCA was derived from staging CT at vertebral levels T12 and L3, including cross-sectional area (CSA) and density of skeletal muscle (SM), subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT). Generalized linear models were used to assess associations between BCA and GS, TUG, and frailty. Amongst 56 patients (median age 71 years; 84% male), increased SM CSA and density at T12 and L3 were associated with lower odds of abnormally low GS (L3: odds ratio [OR] 0.73; 95% confidence interval [CI]: 0.57, 0.94; P = 0.02, and OR 0.65; 95% CI: 0.44, 0.94; P = 0.002, respectively). Increased SM density at T12 and decreased IMAT CSA at T12 and L3 were associated with lower odds of abnormally low TUG (T12: OR 0.58; 95% CI: 0.37, 0.89; P = 0.01, and OR 4.24; 95% CI: 1.31, 13.70; P = 0.02). There was insufficient evidence of an association between BCA and frailty. BCA at T12 and L3 is associated with CGA components GS and TUG. These findings support future investigation of predictive ability of CT-derived biomarkers, including their potential use as surrogates for selected CGA components and their ability to facilitate guideline-concordant risk stratification.
-
7. Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.
PMID:日期:2026-09-26To evaluate serum Galectin-3 levels in patients with non-muscle-invasive bladder cancer (NMIBC) and to investigate their diagnostic performance and ability to discriminate between low-grade and high-grade disease. This prospective controlled study included 80 patients with NMIBC (40 low-grade and 40 high-grade) and 40 age-matched healthy controls. Serum Galectin-3 levels were measured using a commercially available ELISA kit prior to transurethral resection of the bladder tumor. Group comparisons were performed using appropriate parametric and non-parametric statistical tests. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis with bootstrap confidence intervals and internal five-fold cross-validation. Associations between serum Galectin-3 levels and bladder cancer diagnosis and high-grade disease were assessed using univariate logistic regression. Serum Galectin-3 levels differed significantly among the study groups, with the highest levels observed in patients with high-grade NMIBC (P < 0.01). No significant difference was observed between the low-grade and control groups. Galectin-3 demonstrated moderate discrimination between patients with NMIBC and healthy controls (AUC = 0.673), whereas discrimination between high-grade and low-grade NMIBC was more pronounced (AUC = 0.777). Higher serum Galectin-3 levels were associated with bladder cancer diagnosis (OR 1.216, 95% CI, 1.003-1.475, P = 0.046) and with high-grade disease (OR 1.493, 95% CI, 1.097-2.033, P = 0.011). Serum Galectin-3 appears to be associated primarily with high-grade tumor biology rather than with the presence of NMIBC itself. Although its overall diagnostic performance for detecting NMIBC is moderate, it may serve as a complementary biomarker for discriminating high-grade disease. External validation in larger multicenter cohorts is required before clinical application.
-
8. Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.
PMID:日期:2026-09-24To identify patients with high-risk muscle-invasive urothelial carcinoma (MIUC) who derive greater benefit from adjuvant nivolumab after radical surgery. This single-center retrospective study included 246 patients with high-risk MIUC who underwent radical surgery between 2018 and 2025. High-risk disease was defined according to the CheckMate 274 trial criteria. The real-world oncological outcomes of patients who received adjuvant nivolumab (n = 51) were compared with those of a contemporary control cohort (n = 51) and a historical control cohort (n = 144). Prognostic factors for disease-free survival (DFS) in nivolumab-naïve patients were evaluated using multivariate Cox regression analysis. DFS for the entire cohort was stratified according to significant prognostic factors and nivolumab use. The adjuvant nivolumab cohort showed favorable oncological outcomes compared to both the contemporary and historical control cohorts. Multivariate analysis identified lymphovascular invasion (LVI) and nodal positivity as independent prognostic factors in nivolumab-naïve patients. In patients with LVI or nodal positivity, those who received adjuvant nivolumab had a significantly improved DFS compared with those who did not (hazard ratio 0.40; 95% confidence interval, 0.22-0.73; log-rank P = 0.002). However, in patients with neither LVI nor nodal positivity, DFS did not differ significantly according to adjuvant nivolumab use (P = 0.66). Our findings suggest that LVI and nodal positivity may help identify patients with high-risk MIUC who are more likely to benefit from adjuvant nivolumab. These pathological features may serve as practical markers for patient selection; however, further validation is required before clinical implementation.
-
9. Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China.
PMID:日期:2026-09-22To evaluate the efficacy of robot-assisted radical prostatectomy (RARP) combined with androgen deprivation therapy (ADT) vs. ADT alone on oncological outcomes in oligometastatic prostate cancer (OmPCa) patients. This multicenter retrospective analysis included 290 patients with OmPCa who received RARP combined with ADT (n = 170) or ADT alone (n = 120) at 5 Chinese medical centers between December 2008 and December 2023. Inverse probability of treatment weighting was applied to control for confounding factors. Radiographic progression-free survival (rPFS) and overall survival (OS) were used as clinical endpoints to evaluate the impact of RARP combined with ADT on oncological outcomes in patients with OmPCa. After IPTW adjustment, baseline characteristics were well balanced between the 2 groups (all SMD < 0.10). Compared with the non-surgical group, the surgical group had significantly prolonged median rPFS (hazard ratio = 0.24, 95% confidence interval: 0.17-0.33, P < 0.001) and median OS (hazard ratio = 0.22, 95% confidence interval: 0.14-0.33, P < 0.001). Time-varying covariate analysis also supported this finding (both P < 0.001). Exploratory subgroup analyses indicated that, regardless of baseline characteristics, patients in the surgical group had significantly prolonged rPFS and OS (all P < 0.05). RARP combined with ADT was significantly associated with improved oncological outcomes in patients with OmPCa, and this association was independent of baseline characteristics; however, this finding is limited by the relatively small sample size and requires validation in prospective studies.
-
10. Prehabilitation for patients undergoing radical cystectomy: Patient selection and targeted interventions.
PMID:日期:2026-09-22Radical cystectomy (RC) is associated with high perioperative morbidity, reflecting common preoperative vulnerability from frailty, sarcopenia, malnutrition, systemic inflammation, deconditioning (including during neoadjuvant chemotherapy), and psychological distress. Although prehabilitation is safe and feasible and has demonstrated improvements in functional capacity, quality of life, and select postoperative outcomes, real-world uptake remains low, in part due to uncertainty regarding appropriate patient selection and how to operationalize evidence-based interventions. We aimed to provide a pragmatic framework for identifying candidates for prehabilitation before RC and to summarize evidence-based prehabilitative interventions that can be implemented or referred from routine urologic oncology practice. A non-systematic, expert narrative review of contemporary literature was performed, evaluating prehabilitation in bladder cancer and RC populations, with emphasis on feasible clinic-based tools to identify physiologic and psychological vulnerability and on intervention components with demonstrated benefit. Multiple efficient screening approaches can identify candidates for prehabilitation, including frailty indices (e.g., Clinical Frailty Scale, modified frailty indices, claims- or chart-derived frailty tools), functional assessments (e.g., Short Physical Performance Battery, Timed Up & Go, sit-to-stand tests, grip strength, 6-minute walk test), and markers of nutritional risk and catabolism (e.g., albumin, unintentional weight loss, low body mass index (BMI), computed tomography (CT)-based sarcopenia measures, inflammatory markers). Psychological vulnerability (e.g., anxiety/depression, low mental health scores, limited social support) is also associated with worse postoperative recovery and can be screened using brief questionnaires. Evidence supports multimodal prehabilitation incorporating aerobic and resistance exercise, nutritional optimization (primarily targeted perioperative supplementation), and perioperative education (including stoma counseling), with emerging data for stress-management, smoking cessation, and cognitive prehabilitation. Establishing streamlined referral pathways to physical therapy/rehabilitation, nutrition, psychology/psychiatry, and social work improves feasibility. Prehabilitation prior to RC is an actionable, patient-centered strategy to improve functional reserve and recovery, though evidence to date demonstrates inconsistent effects on harder perioperative endpoints such as complications, length of stay, or readmissions. Routine vulnerability screening and standardized referral pathways can increase prehabilitation utilization and may reduce morbidity in this high-risk surgical population.